CARsgen’s Kailimei wins clearance for late-line CLDN18.2-positive, HER2-negative gastric cancer, marking a milestone for cell therapy beyond blood cancers
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
China’s medical regulator has approved a gastric cancer treatment developed by CARsgen Therapeutics, marking the world’s first approval of a chimeric antigen receptor T-cell (CAR-T) therapy for solid tumors.
The world’s first CAR-T therapy for solid tumors has passed muster in China, with the country's National Medical Products…
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
SHANGHAI, June 24, 2026 /PRNewswire/ -- Jiahui International Cancer Center (JICC) welcomes the approval of Satri-cel (CT041,…
Lo indica una sperimentazione condotta in Cina (ANSA)
CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented…
